The Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2015

• Citation: S.I. 2015/233
• Sections: 3

Section 1 Citation and commencement

These Regulations may be cited as the Health Service Medicines (Control of Prices and Supply of Information) (Amendment) Regulations 2015 and come into force on 9th March 2015.

Section 2 Amendment of the Health Service Medicines (Information Relating to Sales of Branded Medicines etc. ) Regulations 2007

(1) The Health Service Medicines (Information Relating to Sales of Branded Medicines etc.) Regulations 2007 are amended as follows.

(2) In regulation 2 (interpretation), in sub-paragraph (c)(iv) of the definition of “branded health service medicine”, after “in relation to Wales” omit “is”.

(3) In regulation 3 (information)—

(a) for paragraph (2) substitute the following paragraph—

(2) The obligation to provide information under this regulation and regulation 3A shall not apply to a manufacturer or supplier of branded health service medicines to whom a voluntary scheme applies (“scheme member”) who has agreed as part of its obligations under the voluntary scheme to provide within the time limits set out in the voluntary scheme such information relating to the sales income in respect of each branded health service medicine as is required by the voluntary scheme.

(b) omit paragraph (4);

(c) in paragraph (5)(a) for “total number of presentations” substitute “quantity of each presentation”; and

(d) for paragraph (8) substitute the following paragraph—

(8) In this regulation and regulation 3A—

“presentation” means a particular form of a relevant medicine which may be distinguished from other forms of the medicine by reference to its active ingredients, strength and excipients, pack size, type of packaging, clinical indications or method of administration or formulation for use in clinical practice; and

“relevant medicine” means a medicine which is both a prescription only medicine and a branded health service medicine.

(4) After regulation 3 (information) insert the following regulation—

Further Information

(3A)

(1) A manufacturer or supplier of branded health service medicines must, in respect of each transaction for each presentation with each purchaser, record and keep, for six years from the date of each transaction, information about—

(a) the sales income actually received; and

(b) the quantity of each presentation sold.

(2) Where the Secretary of State reasonably believes that a manufacturer or supplier of branded health service medicines has breached any of the requirements of these Regulations or the Health Service Branded Medicines (Control of Prices and Supply of Information) ( No. 2) Regulations 2008 , the Secretary of State may require that the manufacturer or supplier provide any information required to be kept by virtue of paragraph (1).

(3) A request under paragraph (2) must be in writing and must specify—

(a) the presentations to which the request relates;

(b) the period of time the information must cover; and

(c) such period, which must not be less than 28 days from the date of the written request, as is reasonable in all the circumstances within which the information must be provided.

(5) In regulation 4(1) (penalties), for “regulation 3(5), (6) or (7) (information requirements)” substitute “regulation 3(5) to (7) (information) or regulation 3A (further information)”.

Section 3 Amendment of the Health Service Branded Medicines (Control of Prices and Supply of Information)(No.2) Regulations 2008

(1) The Health Service Branded Medicines (Control of Prices and Supply of Information) (No.2) Regulations 2008 are amended as follows.

(2) In regulation 1 (citation, commencement and interpretation), in paragraph (2)—

(a) for the definition of “presentation” substitute the following definition—

“presentation” means a particular form of a relevant medicine which may be distinguished from other forms of the medicine by reference to its active ingredients, strength and excipients, pack size, type of packaging, clinical indications or method of administration or formulation for use in clinical practice;

(b) after the definition of “presentation”, insert—

“relevant medicine” means a medicine which is both a prescription only medicine and a branded health service medicine; and

(3) in regulation 2 (control of prices) in paragraph (3)—

(a) omit “or” at the end of paragraph (b);

(b) insert “or” at the end of paragraph (c); and

(c) insert the following paragraph after paragraph (c)—

(d) to any presentation which was procured under one or more framework agreements under the Public Contracts Regulations 2006 —

(i) where the framework agreement was entered into on or before 31st December 2013 or was entered into following a tender which closed on or before 31st December 2013, and

(ii) until the day after the day at the end of which the relevant framework agreement expires.